Sharjah-based corporate venture capital platform CE-Ventures has invested in UK biotech Oyster Therapeutics as part of the company’s $60M Series A financing, according to an announcement on 11 November 2026.
Previously known as Kesmalea Therapeutics, Oyster is developing targeted protein degraders for tau-driven neurodegenerative diseases, including Alzheimer’s. The company’s lead programme is an oral, brain-penetrant degrader designed to target the tau protein.
The financing will support Oyster’s next stage of development and move the lead programme towards clinical development. It will also help advance the company’s SELFTAC platform, which focuses on targeted protein degradation for central nervous system conditions.
The investment expands CE-Ventures’ life sciences portfolio, which includes drug discovery, genetic medicine and targeted therapeutics. Oyster adds neuroscience and targeted protein degradation to the platform’s existing focus.
Source: Zawya
